SC
BOLT icon

Steven Cohen’s Bolt Biotherapeutics BOLT Stock Holding History

Steven Cohen’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,698
Closed -$1.19M – 1100
2021
Q3 		$1.19M Buy
+4,698
New +$1.33M 0.01% 840

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Steven Cohen's BOLT Position: Q4 2021 in Review

Steven Cohen sold out of Bolt Biotherapeutics (BOLT) in Q4 2021, closing a stake of 4,698 shares — an estimated $1.19M sold.

Steven Cohen first reported a position in BOLT in Q3 2021 and held it in 1 quarter. The position peaked at $1.19M in Q3 2021. 62 funds tracked by Wall St. Rank hold BOLT as of Q4 2021.

  • Steven Cohen reported no remaining Bolt Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Steven Cohen sold 4,698 Bolt Biotherapeutics shares in Q4 2021, an estimated $1.19M.
  • Steven Cohen first reported a position in Bolt Biotherapeutics in Q3 2021 and held it in 1 quarter.
  • Steven Cohen's Bolt Biotherapeutics position peaked at $1.19M in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2021.

Based on Point72 Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.